4 November 2013Europe

A changing market: Genomic Vision's IP strategy

When the Supreme Court decided earlier this year that isolated genetic material is not patent-eligible, it opened up the genetic screening market, inevitably introducing a new battleground for asserting IP rights on diagnostic technologies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

GSK triumphs in EPO appeal, revoking Pfizer patent

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

CRISPR patents revoked following Nobel Prize winners’ withdrawal

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

A changing market: Genomic Vision's IP strategy

Editor's picks

Editor's picks

More features